PMID- 22542764
OWN - NLM
STAT- MEDLINE
DCOM- 20121203
LR  - 20131121
IS  - 1769-6690 (Electronic)
IS  - 0399-077X (Linking)
VI  - 42
IP  - 6
DP  - 2012 Jun
TI  - Role of intravenous cloxacillin for inpatient infections.
PG  - 241-6
LID - 10.1016/j.medmal.2011.10.015 [doi]
AB  - One of the issues of antibiotic treatment is to warrant its optimal effectiveness 
      while minimizing the risk for emergence of resistance. The time above minimal 
      inhibiting concentration (MIC) (T>MIC) is the best predictive pharmacological 
      parameter of effectiveness for antibiotics with time-dependent activity, such as 
      cloxacillin. Cloxacillin is the first line antibiotic in a great number of 
      clinical situations generated by methicillin sensitive staphylococci, because of 
      its intrinsic properties: bactericidal effect, tissue distribution and safety. 
      The most recent anti-staphylococcal agents do not improve treatment of MSSA 
      infections compared to penicillin M and especially cloxacillin. Cloxacillin has a 
      narrow microbiological spectrum. This ecological feature is in line with the 
      recommendation to use antibiotics with the narrowest spectrum to reduce the 
      pressure of selection. The consensus is to have T>MIC for at least 40% of the 
      dosing interval and is achieved by infusing 2g of cloxacillin per day (T>MIC=50%) 
      or four infusions of 3g per day (T>MIC=42%) in adults.
CI  - Copyright (c) 2012. Published by Elsevier SAS.
FAU - Bru, J P
AU  - Bru JP
AD  - Service des Maladies Infectieuses, Centre Hospitalier Regional d'Annecy, 1 Avenue 
      de l'Hopital, Metz-Tessy, BP 90074, 74374 Pringy Cedex, France. 
      jpbru@ch-annecy.fr
FAU - Garraffo, R
AU  - Garraffo R
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120427
PL  - France
TA  - Med Mal Infect
JT  - Medecine et maladies infectieuses
JID - 0311416
RN  - 0 (Anti-Bacterial Agents)
RN  - O6X5QGC2VB (Cloxacillin)
SB  - IM
MH  - Anti-Bacterial Agents/*administration & dosage/pharmacology
MH  - Cloxacillin/*administration & dosage/pharmacology
MH  - Humans
MH  - Injections, Intravenous
MH  - Inpatients
MH  - Microbial Sensitivity Tests
MH  - Staphylococcal Infections/*drug therapy
MH  - Staphylococcus aureus/drug effects
EDAT- 2012/05/01 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/05/24 00:00 [received]
PHST- 2011/10/20 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S0399-077X(11)00339-8 [pii]
AID - 10.1016/j.medmal.2011.10.015 [doi]
PST - ppublish
SO  - Med Mal Infect. 2012 Jun;42(6):241-6. doi: 10.1016/j.medmal.2011.10.015. Epub 
      2012 Apr 27.